Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of astragalosides in hepatic stellate cell migration inhibition drug preparation

A technology of hepatic stellate cells and astragalus, applied in the directions of drug combinations, pharmaceutical formulations, plant raw materials, etc., can solve the problems of hepatic stellate cell migration and no related reports.

Inactive Publication Date: 2013-03-27
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no relevant report on the effect of astragalosides on the inhibition of migration of hepatic stellate cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragalosides in hepatic stellate cell migration inhibition drug preparation
  • Application of astragalosides in hepatic stellate cell migration inhibition drug preparation
  • Application of astragalosides in hepatic stellate cell migration inhibition drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] The total astragalus glycosides of the present invention are made into tablets according to methods well known to those skilled in the art. Astragalus total glycosides tablets, each containing 20mg of total astragalus glycosides, 15mg of microcrystalline cellulose, 15mg of micronized silica gel, 0.5mg of magnesium stearate, and 8mg of lactose. Usage: 1 tablet each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

Embodiment 2

[0068] The total astragalus glycosides of the present invention are made into capsules according to methods well known to those skilled in the art. Astragalus total glycosides capsules, each capsule contains 20mg of total astragalus glycosides, 15mg of microcrystalline cellulose, and 10mg of lactose. Usage: 1 capsule each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks is a course of treatment.

Embodiment 3

[0070] The total astragalus glycosides of the present invention are prepared into granules according to methods well known to those skilled in the art. Astragalus total glycosides granules, each bag contains 20mg of total astragalus glycosides, 15mg of microcrystalline cellulose, 15mg of micronized silica gel, 0.5mg of stearic acid, and 8mg of lactose. Usage: 1 bag each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of astragalosides in hepatic stellate cell migration inhibition drug preparation. According to the present invention, a PDGF-induced human hepatic stellate cell line (LX-2) migration screening platform is designed, and results show that PDGF-induced hepatic stellate cell (HSC) migration can be inhibited with 10<-4>-10<-7> mol / L astragalosides.

Description

Technical field [0001] The invention belongs to the field of traditional Chinese medicine, and specifically relates to the application of total astragalus glycosides in preparing medicines for inhibiting migration of hepatic stellate cells. Background technique [0002] Astragalus total glycosides, also known as Astragalus total glycosides, are the main components extracted from Astragalus. It contains flavonoids calycosin, 3-hydroxy-9,10-dimethoxy pterostane, and astragaloside I and V , III (astragaloside I, V, III). It has anti-virus (type II human herpes virus, hepatitis B virus), protects the liver, inhibits the proliferation of liver cancer cell lines and induces their apoptosis, improves heart function, anti-inflammatory and analgesic effects. Animal experiments of total glycosides of astragalus have shown that it can significantly inhibit the proliferation of neutrophils and reduce the levels of cytokines in inflammatory joints, such as interleukin-1 and nitric oxide, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/481A61P1/16
Inventor 徐列明张展
Owner SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com